Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in L'hospitalet De Llobregat – page 210

3 655 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
L'hospitalet De Llobregat at a glance
3 655
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

3 655 trials in L'hospitalet De Llobregat

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Iberdomide and Dexamethasone, Alone or with Drug Combination, for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Fundacion Pethema

Breast cancer female

Not recruiting

Study of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Michelangelo

HIV infection

Not recruiting

Study on Switching from Boosted Protease Inhibitors to Fostemsavir for People with HIV-1 with Limited Treatment Options

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:NEAT ID Foundation

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Chronic hepatitis B

Not recruiting

Study on Bepirovirsen for Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue Treatment

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Metastatic neoplasm

Not recruiting

Study of TAK-280, Tocilizumab, and Siltuximab for Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Takeda Development Center Americas Inc.

Metastatic malignant melanoma

Not recruiting

Study of RO7247669 at Different Doses for People with Previously Untreated Advanced Melanoma that Cannot be Removed by Surgery or Has Spread

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:RO7247669
  • Sponsor:F. Hoffmann-La Roche AG

Hormone-dependent prostate cancer

Not recruiting

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Pneumonia

Not recruiting

Study on Dexamethasone and Sodium Chloride for Treating Severe Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:LEO PHARMA A/S

Renal cell carcinoma

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Advanced Kidney Cancer and Intermediate or Poor Risk Factors

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hormone-refractory prostate cancer

Not recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Novartis Pharma AG

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

  • UTI Vaccine Safety & Efficacy
  • Yellow Fever Immunization
  • RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatment
  • Gastric Cancer Therapies
  • Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

  • Antibody-Mediated Rejection
  • Delayed Graft Function
  • Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

  • Psoriatic Arthritis Treatment
  • Atopic Dermatitis Management
  • Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.